Search

EHA-SWG Scientific Meeting on Systemic Risk of Thrombosis or Bleeding

Jan 15 2020 Posted in Meeting reports

Meeting chairs, Carlo Balduini and Anna Falanga

The meeting was well attended by more than 100 participants coming from over 20 different countries

Delegate: Great meeting.

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Jun 12 2015 Posted in Press releases

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Cookie policy

Introduction
When you visit the EHA website and/or EHA’s resource platform(s) (this includes all websites and pages, with the exemption of www. t2evolve.

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

Nov 23 2022 Posted in Meeting reports

November 10-11, 2022 | Bordeaux, France

Meeting Chairs:
MC Béné, Nantes University
G Zini, Università Cattolica S.

HARMONY: Better care of patients with hematologic malignancies kicked off!

Jan 20 2017

“Combining data available from clinical trials as well as real world patients allows us to do more advanced analyses on possible treatment options that could be effective for individual patient or categories of patients”, said Jesús María Hernandez Rivas, Project…

Congress Sponsor Program

Join us at the EHA Annual Congress, where you have the unique opportunity to connect and grow with a community of hematology experts.